{
    "symbol": "IVA",
    "quarter": 2,
    "year": 2022,
    "date": "2022-09-22 16:36:02",
    "content": " And I would say that we have in front of us two important clinical readouts, one concerning lani, at the beginning of the year, Q1, the results from the study led by Professor Cusi patients with type 2 diabetes in NAFLD and then, of course, the data from the Phase IIb that is currently carried out by our partner AbbVie this year is really, I would say, will be the -- very important event for our company next year."
}